STOCK TITAN

Cosmo Publishes Agenda of AGM 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

Cosmo Pharmaceuticals has announced its Annual General Meeting (AGM) 2025, scheduled for May 30, 2025, at 12:00 CEST in Amsterdam, Netherlands. The meeting agenda includes several key items:

  • Review of the Board's report for FY2024
  • Approval of Annual Report 2024
  • Proposed dividend distribution of €2.05 per ordinary share
  • Board member discharge and elections
  • Articles of association amendments

Chairman Alessandro Della Chà emphasized that the AGM will provide shareholders an opportunity to review achievements and discuss priorities for the ongoing year. The convening notice, explanatory notes, and written proxy have been published on the company's website, with the 2024 Annual Report available in the Financial Reports section.

Cosmo Pharmaceuticals ha annunciato l'Assemblea Generale Annuale (AGM) 2025, prevista per il 30 maggio 2025 alle ore 12:00 CEST ad Amsterdam, Paesi Bassi. L'ordine del giorno comprende diversi punti chiave:

  • Esame della relazione del Consiglio per l'esercizio 2024
  • Approvazione del Rapporto Annuale 2024
  • Proposta di distribuzione di dividendi pari a €2,05 per azione ordinaria
  • Approvazione della gestione e rinnovo del Consiglio di Amministrazione
  • Modifiche allo statuto sociale

Il Presidente Alessandro Della Chà ha sottolineato che l'AGM offrirà agli azionisti l'opportunità di valutare i risultati ottenuti e discutere le priorità per l'anno in corso. L'avviso di convocazione, le note esplicative e la delega scritta sono disponibili sul sito web della società, mentre il Rapporto Annuale 2024 è consultabile nella sezione Rapporti Finanziari.

Cosmo Pharmaceuticals ha anunciado su Junta General Anual (AGM) 2025, programada para el 30 de mayo de 2025 a las 12:00 CEST en Ámsterdam, Países Bajos. La agenda de la reunión incluye varios puntos clave:

  • Revisión del informe del Consejo para el año fiscal 2024
  • Aprobación del Informe Anual 2024
  • Propuesta de distribución de dividendos de €2,05 por acción ordinaria
  • Descargo y elecciones de miembros del Consejo
  • Modificaciones a los estatutos sociales

El presidente Alessandro Della Chà destacó que la AGM brindará a los accionistas la oportunidad de revisar los logros y debatir las prioridades para el año en curso. El aviso de convocatoria, las notas explicativas y el poder escrito están publicados en la página web de la compañía, y el Informe Anual 2024 está disponible en la sección de Informes Financieros.

코스모 파마슈티컬스는 2025년 5월 30일 오후 12시 CEST에 네덜란드 암스테르담에서 개최될 2025년 연례 주주총회(AGM)를 발표했습니다. 회의 안건에는 다음과 같은 주요 항목들이 포함되어 있습니다:

  • 2024 회계연도 이사회 보고서 검토
  • 2024 연례 보고서 승인
  • 보통주 1주당 €2.05 배당금 분배 제안
  • 이사 해임 승인 및 선출
  • 정관 개정

알레산드로 델라 차 의장은 이번 AGM이 주주들에게 성과를 검토하고 올해의 우선순위를 논의할 기회를 제공할 것이라고 강조했습니다. 소집 공고, 설명 자료 및 서면 위임장은 회사 웹사이트에 게시되어 있으며, 2024년 연례 보고서는 재무 보고서 섹션에서 확인할 수 있습니다.

Cosmo Pharmaceuticals a annoncé son Assemblée Générale Annuelle (AGM) 2025, prévue le 30 mai 2025 à 12h00 CEST à Amsterdam, Pays-Bas. L'ordre du jour comprend plusieurs points clés :

  • Examen du rapport du Conseil d'administration pour l'exercice 2024
  • Approbation du Rapport Annuel 2024
  • Proposition de distribution d'un dividende de 2,05 € par action ordinaire
  • Quitus aux membres du Conseil et élections
  • Modifications des statuts

Le président Alessandro Della Chà a souligné que l'AGM offrira aux actionnaires l'occasion de passer en revue les réalisations et de discuter des priorités pour l'année en cours. L'avis de convocation, les notes explicatives et la procuration écrite ont été publiés sur le site internet de la société, le Rapport Annuel 2024 étant disponible dans la section Rapports Financiers.

Cosmo Pharmaceuticals hat seine ordentliche Hauptversammlung (AGM) 2025 für den 30. Mai 2025 um 12:00 CEST in Amsterdam, Niederlande, angekündigt. Die Tagesordnung umfasst mehrere wichtige Punkte:

  • Bericht des Vorstands für das Geschäftsjahr 2024
  • Genehmigung des Jahresberichts 2024
  • Vorgeschlagene Dividendenzahlung von €2,05 je Stammaktie
  • Entlastung und Wahl der Vorstandsmitglieder
  • Änderungen der Satzung

Vorsitzender Alessandro Della Chà betonte, dass die AGM den Aktionären die Möglichkeit bietet, erreichte Erfolge zu überprüfen und Prioritäten für das laufende Jahr zu diskutieren. Die Einberufungsmitteilung, erläuternde Hinweise und die schriftliche Vollmacht sind auf der Website des Unternehmens veröffentlicht, der Jahresbericht 2024 ist im Bereich Finanzberichte verfügbar.

Positive
  • Proposed dividend distribution of EUR 2.05 per ordinary share from freely distributable reserves
Negative
  • None.

Dublin, Ireland--(Newsfile Corp. - April 29, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo” or the “Company”) today announced the convening of its Annual General Meeting 2025 to be held on Friday 30 May 2025, at 12:00 CEST, at Strawinskyhuis, Prinses Amaliaplein 3, 1077 XS Amsterdam, the Netherlands. The agenda includes, inter alia, the following discussion and voting items:

  • Report of the Board of Directors on the financial year ended 31 December 2024
  • Approval of the Annual Report 2024
  • Appropriation of the FY2024 result
  • Proposal to grant discharge to the members of the Board of Directors
  • Proposal to adopt the proposed resolution of the Board of Directors to declare a distribution of EUR 2.05 per ordinary share out of Cosmo's freely distributable reserves
  • Proposal to grant ordinary shares and/or the right to subscribe for ordinary shares to the members of the Board of Directors  
  • Election of the members of the Board of Directors
  • Proposal to amend the articles of association of the Company

The convening notice and explanatory notes as well as the written proxy have been published today in the AGM section of the Company’s website while the 2024 Annual Report can be found in the Financial Reports section of the Company’s website.

Alessandro Della Chà, Chairman of Cosmo, commented: “The Board of Directors of Cosmo is pleased to issue the 2025 AGM invitation to the shareholders of our Company. This event will provide an opportunity to review our achievements, discuss our priorities for the ongoing year, and address any questions our shareholders may have.”

About Cosmo

Cosmo Pharmaceuticals N.V. is committed to revolutionizing healthcare and transforming people’s lives by researching and developing innovative products that tackle unfulfilled healthcare demands. As a pharmaceutical company, Cosmo is active in the areas of Healthtech/AI, dermatology, gastroenterology and contract manufacturing & development. For the commercialization and distribution of its products, Cosmo collaborates with leading partners worldwide, including Medtronic and Sun Pharma. Founded in 1997, Cosmo is headquartered in Dublin (Ireland) and has offices also in San Diego (USA), and Lainate/Rome/Catania (Italy). The Company has approximately 330 employees at the end of 2024, all dedicated to making a significant impact in the field of healthcare. For more information, please visit www.cosmopharma.com.

Upcoming Events

Annual General Meeting of Shareholders

Jefferies Healthcare Conference, New York

Investor Day, Zurich

May 30, 2025

June 3-5, 2025

July 1, 2025

Half-Year Results 2025

July 23, 2025

 

For further information, please contact:

investor.relations@cosmopharma.com

Attachments

PDF - English

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/250103

FAQ

When is Cosmo's 2025 Annual General Meeting (CMOPF)?

Cosmo's 2025 AGM will be held on Friday, May 30, 2025, at 12:00 CEST in Amsterdam at the Strawinskyhuis.

What is the dividend distribution proposed for Cosmo (CMOPF) shareholders in 2025?

The Board proposes a distribution of EUR 2.05 per ordinary share from Cosmo's freely distributable reserves.

What are the key agenda items for Cosmo's 2025 AGM (CMOPF)?

Key items include approval of the 2024 Annual Report, FY2024 result appropriation, dividend distribution proposal, Board member elections, and amendments to company articles of association.

Where can shareholders find Cosmo's 2025 AGM documents (CMOPF)?

The convening notice, explanatory notes, and written proxy are available in the AGM section of Cosmo's website, while the 2024 Annual Report is in the Financial Reports section.

Will Cosmo (CMOPF) grant new shares to Board members in 2025?

The AGM agenda includes a proposal to grant ordinary shares and/or subscription rights for ordinary shares to Board of Directors members.
Cosmo Pharmaceuticals Nv

OTC:CMOPF

CMOPF Rankings

CMOPF Latest News

CMOPF Stock Data

1.18B
7.72M
47.29%
12.92%
Drug Manufacturers - General
Healthcare
Link
Ireland
Dublin